Press release
Spasticity Clinical Trial Analysis 2026: In-Depth Evaluation of 12+ Emerging Therapies Across 10+ Leading Companies, Reports DelveInsight
Spasticity Clinical Trial
DelveInsight's publication, "Spasticity Pipeline Insight, 2026" presents a detailed analysis of the present clinical development scenario along with future market projections for Spasticity.
The report delivers a thorough commercial and clinical examination of pipeline assets, spanning from preclinical stages to approved products. It features detailed drug profiles outlining mechanisms of action, updates from clinical trials, regulatory achievements such as NDA submissions, and broader product development initiatives, including technological innovations, strategic partnerships, licensing arrangements, mergers and acquisitions, financial investments, special regulatory designations, and other significant updates.
Download a complimentary sample copy to explore upcoming therapies @ https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Major Insights from the Spasticity Pipeline Report
• Pharmaceutical companies worldwide are actively advancing novel therapeutic options for Spasticity, demonstrating substantial developmental progress in recent years.
• Key organizations engaged in Spasticity drug development include Lundbeck, Revance Therapeutics, Ipsen, Saol Therapeutics, Huons, Supernus Pharma, Sun Pharma, Acorda Therapeutics, Merz Pharmaceuticals GmbH, Medy-Tox, XenoPort, Inc., Medtronic Neuro, Daewoong Pharma, among others.
• Notable emerging therapies progressing through clinical stages include Lu AG06466, DAXXIFY, IPN10200, SL-1002, HU-014, MYOBLOC, SPARC1103, Tizanidine, CORETOX®, XP19986 SR1, intrathecal baclofen, and Botulinum toxin type A, each anticipated to play a significant role in transforming the Spasticity treatment paradigm in the years ahead.
Recent Clinical and Regulatory Updates in Spasticity
• July 2025: A global Phase II study, BALANCE-MSS-1 (NCT06782490), initiated enrollment of approximately 200 adult patients with multiple sclerosis-associated spasticity to assess Bristol Myers Squibb's oral investigational therapy BMS-986368. Conducted across the United States, Europe, Australia, Canada, and Puerto Rico, the trial is sponsored by Celgene, which now operates under Bristol Myers Squibb.
• April 2025: The U.S. FDA granted clearance to BlackfinBio's IND application for a Phase I/II clinical study evaluating BFB-101, an AAV-based gene therapy targeting hereditary spastic paraplegia type 47 (SPG47). The therapy has received orphan drug and rare pediatric disease designations and focuses on AP4B1 gene mutations responsible for progressive spasticity and developmental challenges in pediatric patients.
• March 2025: BlackfinBio confirmed the submission of its IND application for the same AAV gene therapy candidate intended for SPG47 treatment.
• January 2024: Neurotech International secured authorization from the Human Research Ethics Committee (HREC) and Australia's Therapeutic Goods Administration (TGA) to commence a Phase I/II clinical trial evaluating NTI164 in pediatric patients with spastic cerebral palsy, the most common form of cerebral palsy.
Access the Free Sample PDF Report to gain deeper insights into the Spasticity therapeutic pipeline - https://www.delveinsight.com/report-store/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Spasticity Overview
Spasticity is a neurological condition marked by heightened muscle tone or stiffness, which can impair mobility, speech, and walking patterns. It generally arises due to injury or dysfunction in the brain or spinal cord, disrupting neural pathways that regulate voluntary muscle movement.
Emerging Therapies Under Development for Spasticity
Significant pipeline candidates include:
• Lu AG06466 - Lundbeck
• DAXXIFY - Revance Therapeutics
• IPN10200 - Ipsen
• HU-014 - Huons
• SL-1002 - Saol Therapeutics
• MYOBLOC - Supernus Pharma
• SPARC1103 - Sun Pharma
• Tizanidine - Acorda Therapeutics
• Botulinum toxin type A - Merz Pharmaceuticals GmbH
• CORETOX® - Medy-Tox
• XP19986 SR1 - XenoPort, Inc.
• Intrathecal baclofen - Medtronic Neuro
Comprehensive product-level insights are detailed within the report. Download the Spasticity pipeline analysis to learn more about the advancing treatment landscape - https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Routes of Administration (ROA) in the Spasticity Pipeline
Pipeline therapies for Spasticity are being developed across multiple administration routes, including:
• Oral formulations
• Parenteral delivery
• Intravenous administration
• Subcutaneous injection
• Topical applications
Molecule Types in Development
The Spasticity pipeline reflects a diverse molecular spectrum, including:
• Monoclonal antibodies
• Peptides
• Polymer-based therapies
• Small molecules
• Gene therapy platforms
Therapeutic Evaluation Framework
The report delivers:
• Product type-based assessments
• Segmentation by clinical development stage
• Detailed route of administration analysis
• Stage-wise evaluation of ROA
• Classification by molecule type
• Phase-specific molecular categorization
DelveInsight profiles more than 12 pipeline candidates across various development phases, including:
• Late-stage (Phase III) programs
• Mid-stage (Phase II) assets
• Early-stage (Phase I) candidates
• Preclinical and discovery-stage therapies
• Discontinued and inactive projects
Download the sample PDF to gain further knowledge about Spasticity drugs and therapeutic innovations - https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Spasticity Pipeline Evaluation
The analysis covers:
• Company-specific therapeutic portfolios, including both active and discontinued programs
• Stage-based categorization of pipeline therapies
• Classification of treatments by route of administration, mechanism of action, monotherapy versus combination approach, and molecular composition
• In-depth coverage of strategic alliances, academic collaborations, licensing deals, and funding initiatives
• Insights derived from proprietary databases, clinical trial registries, corporate disclosures, SEC filings, investor communications, conference presentations, and validated third-party data sources
Market Growth Drivers for Spasticity
• Increasing prevalence of stroke, multiple sclerosis, and traumatic brain injuries
• Expanding research and development initiatives focused on targeted and effective Spasticity therapies
Spasticity Market Challenges
• Elevated treatment costs
• Insufficient disease awareness in emerging and developing regions
• Additional factors limiting widespread therapy adoption
Scope of the Spasticity Market Analysis
• Geographical Coverage: Global
• Major Companies: Lundbeck, Revance Therapeutics, Ipsen, Saol Therapeutics, Huons, Supernus Pharma, Sun Pharma, Acorda Therapeutics, Merz Pharmaceuticals GmbH, Medy-Tox, XenoPort, Medtronic Neuro, Daewoong Pharma, and others
• Key Therapies: Lu AG06466, DAXXIFY, IPN10200, SL-1002, HU-014, MYOBLOC, SPARC1103, Tizanidine, CORETOX®, XP19986 SR1, intrathecal baclofen, Botulinum toxin type A, and more
• Therapeutic Coverage: Existing and pipeline therapies
• Market Dynamics: Comprehensive review of factors driving and restraining growth within the Spasticity market
Request a Sample PDF for the Spasticity Pipeline Assessment and clinical trial insights - https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Spasticity Clinical Trial Analysis 2026: In-Depth Evaluation of 12+ Emerging Therapies Across 10+ Leading Companies, Reports DelveInsight here
News-ID: 4401922 • Views: …
More Releases from DelveInsight Business Research
Retinitis Pigmentosa Pipeline 2026: FDA Approvals and Clinical Trials Landscape …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Retinitis Pigmentosa pipeline constitutes 20+ key companies continuously working towards developing 25+ Retinitis Pigmentosa treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Retinitis Pigmentosa Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Retinitis Pigmentosa Market.
The Retinitis…
Multiple Sclerosis Pipeline 2026: Therapies, MOA Insights, and Key Clinical Tria …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Multiple Sclerosis pipeline constitutes 75+ key companies continuously working towards developing 80+ Multiple Sclerosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Multiple Sclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…
Car T Cell Therapy For Multiple Myeloma Pipeline 2026: MOA, ROA, FDA-Approved Dr …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Car T Cell Therapy For Multiple Myeloma pipeline constitutes 5+ key companies continuously working towards developing 5+ Car T Cell Therapy For Multiple Myeloma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Car T Cell Therapy For Multiple Myeloma Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into…
Spinocerebellar Ataxias Pipeline 2026: Therapies Under Investigation, Clinical T …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Spinocerebellar Ataxias pipeline constitutes 8+ key companies continuously working towards developing 10+ Spinocerebellar Ataxias treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Spinocerebellar Ataxias Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinocerebellar Ataxias Market.
The Spinocerebellar…
More Releases for Spasticity
Spasticity Market: Rapid Growth & Investment Outlook to 2032 - DelveInsight
The Spasticity market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Spasticity pipeline products will significantly revolutionize the Spasticity market dynamics.
DelveInsight's "Spasticity Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Spasticity, historical and forecasted epidemiology as well as the Spasticity market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Spasticity Market 2025-2034 Business Outlook, Critical Insight and Growth
Introduction
Spasticity is a motor disorder characterized by involuntary muscle stiffness, spasms, and exaggerated reflexes caused by damage to the central nervous system (CNS). It frequently occurs as a complication of stroke, multiple sclerosis (MS), cerebral palsy, traumatic brain or spinal cord injury, and other neurological conditions. Spasticity can severely impact mobility, daily functioning, and quality of life, making it a significant healthcare burden worldwide.
Treatment approaches combine pharmacological agents, intrathecal therapies,…
Muscle Spasticity Market Emerging Trends and Growth Prospects 2034
Introduction
Muscle spasticity is a condition characterized by involuntary muscle stiffness, spasms, and increased tone, often resulting from neurological disorders such as multiple sclerosis, cerebral palsy, stroke, or traumatic brain and spinal cord injuries. It significantly impacts mobility and quality of life, making effective management essential. With the rising incidence of neurological diseases and advancements in physiotherapy, drug therapies, and medical devices, the global muscle spasticity market is witnessing steady expansion.
According…
Spasticity Drugs Top Companies Regional and Data Analysis to 2031
The Spasticity Drugs Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits.
Download PDF Brochure at: https://www.theinsightpartners.com/sample/TIPRE00040811/?utm_source=OpenPR&utm_medium=10129
Major Companies operating in the Spasticity Drugs Market are:
• Ipsen Pharma
• Allergan
• Acorda Therapeutics, Inc.
• Merz Pharma
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Beximco Pharmaceuticals Ltd.
• Johnson & Johnson Private Limited
• Zydus Cadila
Contact Us:
If you have any queries about this report or if…
Spasticity Treatment Market Expecting Huge Demand in Upcoming Years
The Global Spasticity Treatment Market size is estimated at $5.7 Billion in 2025 and is forecast to register an annual growth rate (CAGR) of 4.9% to reach $8.8 Billion by 2034. Download now
The latest study released on the Global Spasticity Treatment Market by USD Analytics Market evaluates market size, trend, and forecast to 2034. The Spasticity Treatment market study covers significant research data and proofs to be a handy resource…
Muscle Spasticity Market Growth, Research Report, Analysis & Trends 2023-2033
Muscle Spasticity Market Report Overview:
Report Attribute Details
Base Year 2022
Forecast Years …
